Immune technology

The Immunotechnology working group at UP Transfer GmbH has established itself in the region as a reliable project partner for the generation of monoclonal antibodies and the development of various immunoassays. Monoclonal antibodies are indispensable tools in medical diagnostics and bioanalytics and are the most frequently used binding molecules. The generation of such monoclonal antibodies is carried out using hybridoma technology. This is a highly specialized service which, in addition to the necessary laboratory equipment, requires extensive technical knowledge and experience on the part of the staff.

As a rule, our customers and project partners are interested in detecting a substance quickly and easily or bringing a system for its detection onto the market. The substances to be detected can be of importance in a wide variety of contexts. As a rule, these come mainly from the fields of environmental analysis, medical diagnostics, veterinary medicine, food analysis or process control.

We design a concept for the detection of the relevant substances, develop and establish such a detection method and generate new biological materials (e.g. antibodies) that are required and used in this method.

Close and trusting cooperation with our project partners and customers is essential for the successful completion of projects. This is essential in order to be able to offer a service that is precisely tailored to the requirements of our customers. We are also happy to be your partner for projects funded by the federal government (e.g. ZIM, BMBF) or the federal states (transfer bonus, innovation voucher). Our team consists of employees with many years of experience in the fields of immunology, biotechnology and cell culture technology as well as knowledge of project and quality management.

We provide our customers and project partners with expertise in the following areas:

1. Generation of monoclonal mouse antibodies against any antigens. In particular, we have many years of experience in the relatively complex generation of antibodies against low-molecular substances (e.g. fluorescent dyes, mycotoxins, steroid hormones, etc.). Some of these antibodies are already used in commercial assays (references available on request). We can also offer an alternative animal model for special questions.
2. Development of standard ELISA systems, direct, indirect and competitive. We have a broad portfolio of monoclonal antibodies and work closely with companies and research groups that develop and produce chemical conjugates for such assays.
3. Development of novel homogeneous immunoassays based on fluorescence-modulating antibodies. These assays can be performed and measured in less than 10 minutes “point of care”.